Publication dates

All regions

Rheumatoid Arthritis Industry, October 2014 Market Reports from Top Publishers

You might be interested in: medical equipment, therapeutics, disease testing, more »


 
1-20 of about 8 900 reports for Rheumatoid Arthritis

Bone Medical Limited (Symbol:BNE) SWOT Analysis, Strategy, Revenues and Profits

Bone Medical Limited (Symbol:BNE) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • October 2014
  • by Global Data

... To prevent bone and joint diseases and conditions, such as osteoporosis, osteoarthritis, and rheumatoid arthritis. Its projects include capthymone, capsitonin, tnf regularors bn006 and bone cell regulators bn ...

Can-Fite BioPharma Ltd. (Symbol:CFBI) SWOT Analysis, Strategy, Revenues and Profits

Can-Fite BioPharma Ltd. (Symbol:CFBI) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • October 2014
  • by Global Data

... Of rheumatoid arthritis, glaucoma and psoriasis. Its cf 102, is an oral drug used to treat liver cancer and cf 602, is an allosteric modulator used in the treatment of inflammatory diseases. The company conducts ...

Cellceutix Corporation (Symbol:CTIX) SWOT Analysis, Strategy, Revenues and Profits

Cellceutix Corporation (Symbol:CTIX) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • October 2014
  • by Global Data

... Multiple tumors, cand targeting psoriasis, cand targeting rheumatoid arthritis, cand with potential for indications of osteo-arthritis or asthma, and others. It provides services in the areas ...

Galapagos NV (Symbol:GLPGA) SWOT Analysis, Strategy, Revenues and Profits

Galapagos NV (Symbol:GLPGA) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • October 2014
  • by Global Data

... Glpg0778/555 is used for the treatment of immuno and inflammatory diseases. Galapagos's glpg0634 is an orally-available, selective inhibitor of jak1 used for the treatment of rheumatoid arthritis ...

Neovacs SA (Symbol:ALNEV) SWOT Analysis, Strategy, Revenues and Profits

Neovacs SA (Symbol:ALNEV) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • October 2014
  • by Global Data

... Of autoimmune and inflammatory diseases. Its products under clinical development include tnf-kinoid and ifna-kinoid. Neovacs's products are used in the treatment of rheumatoid arthritis, crohn's disease, cancer ...

Acasti Pharma Inc. (APO) - Financial and Strategic SWOT Analysis Review

Acasti Pharma Inc. (APO) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • October 2014
  • by Global Data

... Phospholipids and antioxidants purified from the precursor neptune krill oil. It serves patients with atherosclerosis, diabetes, rheumatoid arthritis, and gastroenterology disorders. The company operates ...

Entia Biosciences, Inc. (ERGO) - Financial and Strategic SWOT Analysis Review

Entia Biosciences, Inc. (ERGO) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • October 2014
  • by Global Data

... Hemo, ergo-d2-flex-ra, and ergo-d2-hsn. The company's ergo-d2-hemo is a medical nutrition solution used for treatment of diabetes and anemia; ergo-d2-flex-ra is solution used to treat rheumatoid ...

GelStat Corporation - Strategic SWOT Analysis Review

GelStat Corporation - Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • October 2014
  • by Global Data

... The company's gelstat arthritis is a non-steroidal anti-inflammatory drug used in the treatment of fever, pain, pain associated with inflammation in rheumatoid arthritis and osteoarthritis, neuromuscular ...

Santen S.A.S. - Strategic SWOT Analysis Review

Santen S.A.S. - Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • October 2014
  • by Global Data

... Market. Its products are used for the treatment of corneal and conjunctival disorders, glaucoma and ocular hypertension, retinal / uveal disorders, ocular infections / allergies, and rheumatoid arthritis ...

Portola Pharmaceuticals, Inc. (PTLA) - Financial and Strategic SWOT Analysis Review

Portola Pharmaceuticals, Inc. (PTLA) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • October 2014
  • by Global Data

... Thrombocytopenic purpura, rheumatoid arthritis, systemic lupus erythematosus, asthma and b cell cancers. The company has partnerships with biogen idec for the development of prt2607. It also has collaborations ...

About 1 100 reports for Rheumatoid Arthritis

Download Unlimited Documents from Trusted Public Sources

Pathology Description in the US

  • Medical Policy
  • January 2013
    17 pages
  • Orthopedic  

    Ankle Replaceme...  

  • United States  

View report >

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.